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roles in the homeostatic regulation of B cell functions
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TNF receptor (TNFR) superfamily members, CD40, and Mackay et al., 2003). In BCMA-deficient mice, no gross
BAFFR play critical roles in B cell survival and differen- effect on B cell development or antigen-specific immune
tiation. Genetic deficiency in a novel adaptor molecule, responses has been observed. In contrast, mature B
Act1, for CD40 and BAFF results in a dramatic increase cells accumulate in TACI-deficient mice, suggesting that
in peripheral B cells, which culminates in lymphade- TACI may negatively regulate B cell survival and devel-
nopathy and splenomegaly, hypergammaglobulinemia, opment (Yan et al., 2001; Seshasayee et al., 2003).
and autoantibodies. While the B cell-specific Act1 Lastly, mice expressing a naturally mutated form of
knockout mice displayed a similar phenotype with less BAFFR (the A/WySnJ strain) exhibit peripheral B cell
severity, the pathology of the Act1-deficient mice was abnormalities comparable to those found in BAFF (Blys/
mostly blocked in CD40-Act1 and BAFF-Act1 double TALL-1)-deficient mice, indicating that BAFF-BAFFR in-
knockout mice. CD40- and BAFF-mediated survival is teraction is primarily responsible for peripheral B cell
significantly increased in Act1-deficent B cells, with survival and development (Thompson et al., 2001).
stronger IB phosphorylation, processing of NF-B2 CD40 and BAFFR ligation activate the NFB family of
(p100/p52), and activation of JNK, ERK, and p38 path- transcription factors, which are critical for the regulation
ways, indicating that Act1 negatively regulates CD40- of B cell survival and development. NFB transcription
and BAFF-mediated signaling events. These findings factors are homo- or heterodimers of a group of structur-
demonstrate that Act1 plays an important role in the ally related proteins, including Rel (c-Rel), RelA (p65),
homeostasis of B cells by attenuating CD40 and RelB, NFB1 (p50 and its precursor p105), and NFB2
BAFFR signaling. (p52 and its precursor p100) (Ghosh and Karin, 2002).
In resting cells, most NFB/Rel dimers are bound to
Introduction IBs and retained in the cytoplasm. Upon stimulation
with CD40L and BAFF, the IB proteins are phosphory-
The CD40 (CD40L/CD154)-CD40 ligand and BAFF-BAFF lated by IB kinase (IKK) (DiDonato et al., 1997; Mercurio
receptor (BAFFR) cytokine systems, members of the et al., 1997; Regnier et al., 1997; Woronicz et al., 1997;
Zandi et al., 1997). IKK is composed of the catalytic
subunits IKK and IKK and the regulatory subunit IKK.*Correspondence: lix@ccf.org
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It has been shown that IKK, but not IKK, is mainly to BALB/c. Heterozygous mice (F1) were obtained and
bred to homozygotes (Figure 1C).responsible for the IB phosphorylation, which is fol-
Act1 expression is induced in mouse tissues uponlowed by rapid ubiquitination and degradation of the
intraperitoneal injection of lipopolysaccride (LPS) (ZhaoIB proteins (Karin and Ben Neriah, 2000; Ghosh et al.,
et al., 2003). Act1 expression is also induced in mouse1998), releasing NFB (p65/p50) to activate transcription
splenic B cells upon stimulation with BAFF, CD40L, andin the nucleus (the canonical NFB activation pathway).
LPS, implicating its important role in B cell functionConditional deletion of IKK results in the rapid loss of
(Figure 1D). The LPS-induced expression of Act1 inB cells (Li et al., 2003; Pasparakis et al., 2002), indicating
mouse splenic B cells was no longer detectable in Act1-that the canonical NFB activation pathway mediated
deficient mice (Figure 1D). The expression patterns areby IKK is probably required for the general differentia-
consistent with a negative modulating role for Act1 dur-tion and homeostasis of B cells. CD40 and BAFFR are
ing B cell activation.also able to induce a noncanonical NFB2 processing
The Act1-deficient mice displayed major lymphoidpathway; that is, IKK leads to the phosphorylation and
system abnormalities as early as 3 weeks of age. Theprocessing of p100, resulting in the formation of an ac-
lymph nodes (cervical, axillary, and brachial) were mas-tive RelB/p52 heteodimer (Coope et al., 2002; Kayagaki
sively enlarged (Figure 2A). Lymphadenopathy is due toet al., 2002). NFB inducing kinase (NIK) was shown to
lymphoid hyperplasia, increased germinal centers, andplay a role in activating IKK, leading to p100 processing
the accumulation of large numbers of immunoglobulin-(Ninomiya-Tsuji et al., 1999; Irie et al., 2000; Takaesu et
producing plasma cells (Syndecan-1-positive cells) inal., 2000; Takaesu et al., 2001; Qian et al., 2001; Deng
the medulla of the lymph nodes (Figure 2B). Act1-defi-et al., 2000; Wang et al., 2001; Yin et al., 2001; Garceau
cient mice also developed enlarged spleens (Figure 2A).et al., 2000). The fact that mature B cell numbers are
The microscopic structure of the spleen was largelyreduced in mice lacking NIK or p52 and in irradiated
unaltered, although increased density of B cell zonesmice reconstituted with IKK-deficient lymphocytes
was observed in some of the Act1-deficient spleens assuggests the important role of this noncanonical NFB
compared to wild-type littermate controls (KO2 com-activation pathway in CD40 and BAFFR-mediated B
pared to WT2 in Figure 2C). Furthermore, the Act1-defi-cell survival.
cient mice developed inflammation in multiple tissues,CD40 and BAFFR utilize TRAF (TNF receptor-associ-
including upper respiratory airway and skin (Figure 2Dated factor) molecules as receptor-proximal adapters to
and Supplemental Figure S2 available online at http://mediate the activation of downstream kinases including
www.immunity.com/cgi/content/full/21/4/575/DC1/).IKKs and MAP kinases (Xu and Shu, 2002; Hostager and
Bishop, 1999). We recently identified a novel adaptor
Hypergammaglobulinemia in Act1-Deficient Micemolecule called Act1 that may function as an important
In the CD40-deficient mice, the constitutive levels ofregulator in signaling pathways mediated by CD40 and
immunoglobulins including IgG1, IgG2a, IgG2b, and IgEBAFF. Endogenous Act1 is recruited to CD40 in B cells
are much lower as compared to wild-type control miceupon stimulation with CD40 ligand (CD40L). Act1 does
(Figure 3A and Supplemental Figures S3A and S3B).not have any enzymatic domains; instead it contains a
In contrast, IgG subclasses and IgE were substantiallyhelix-loop-helix at the N terminus and a coiled-coil at
increased, more than 10-fold, in the Act1-deficient micethe C terminus (Qian et al., 2002; Li et al., 2000; Leonardi
as compared to those in the wild-type control mice.et al., 2000). In addition, Act1 contains two putative
However, the levels of IgM, IgG3, and IgA were notTRAF binding sites, EEESE (residues 38–42), and EERPA
changed in either CD40- or Act1-deficient mice (Figure(residues 333–337) (Qian et al., 2002). To elucidate the
3A and Supplemental Figure S3A). The hypergammaglo-physiological functions of Act1, we generated Act1-defi-
bulinemia in Act1-deficient mice is consistent with thecient mice. Act1-deficient mice revealed major lymphoid
increased numbers of plasma cells in the secondarysystem defects, which is marked with lymphadenopa-
lymphoid system of the Act1-deficient mice. Interest-
thy, hypergammaglobulinemia, and production of auto-
ingly, mice that overexpress BAFF display a very similar
antibodies. A general increase in the numbers of periph-
phenotype to the Act1-deficient mice, including lymph-
eral B cells, and CD40- and BAFFR-mediated B cell adenopathy and hypergammaglobulinemia (Gross et al.,
survival is significantly increased in Act1-deficient mice, 2000; Mackay et al., 1999). Taken together, Act1 proba-
indicating that Act1 is an important modulator in humoral bly functions as an important modulator in humoral im-
immune responses by regulating CD40 and BAFFR sig- mune responses, possibly through its involvement in
naling in B cells. CD40- and/or BAFF-mediated pathways.
To determine whether Act1 indeed exerts its regula-
Results tory role in humoral immune responses through the
CD40 and BAFF pathways, we generated CD40-Act1
Lymphoid System Defects in Act1-Deficient Mice and BAFF-Act1 double knockout mice. Both the CD40-
To generate Act1 null mice, the Act1 targeting construct Act1 and BAFF-Act1 knockout mice had much reduced
bearing a disrupted exon 2 (encoding residues 1–268) enlargement of lymph nodes and spleen as compared
was transfected into ES cells derived from the 129/sv to Act1-deficient mice (data not shown). The hypergam-
mouse strain, followed by the transfection of Cre to maglobulinemia observed in Act1-deficient mice was
remove the Neo drug marker and the exon 2 of Act1 abolished in CD40-Act1 and BAFF-Act1 double knock-
(Figure 1A). Targeted ES clones containing the complete out mice (Figure 3A and Supplemental Figure S3A).
Act1 null allele were injected into blastocysts derived These results strongly suggest that Act1 modulates the
from BALB/c mice (Act1 null allele, Figures 1A and 1B). humoral immune responses through its interaction with
the CD40- and BAFF-mediated pathways.Germline- transmitted chimeras were obtained and bred
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Figure 1. Generation of Act1-Deficient Mice
(A) Construction of the Act1 gene-targeting vector. See the Experimental Procedures for details. The gene encoding Act1 (wt allele); the
targeting vector (targeting vector); loxP sequences (filled triangles), left arm (LA); right arm (RA), Diphtoxin A gene (DTA); the targeted allele
with the targeting vector (floxed allele); Cre-mediated complete deletion of the Act1 null allele (Act1 null).
(B and C) Southern blot analyses of DNA from Act1-deficient mice and ES cells. Genomic DNA was extracted from mouse tail tissue or ES
cells, digested with HindIII or KpnI/SpeI, and analyzed by Southern blot by using the two probes (prb1 and prb2) shown in (A). Southern
analysis with prb1 (digested with Kpn1/Spe1) generates a 9.0 kb for the wild-type allele and a 7.0 kb for the Act1 null allele. Southern blot
with prb2 (digested with HindIII) generates a 7.0 kb for the wild-type allele and a 5.0 kb band presents the Act1 null allele.
(D) RNA blot analysis. Total RNA was extracted from wild-type (/) or Act1-deficient (/) splenic B cells, untreated (C1 and C2, incubated
without ligand for 24 or 48 hr, respectively), or treated with BAFF, CD40 antibody, or LPS for 24 or 48 hr. The probes are full-length mouse
cDNAs (right margins: ACT1, Act1; GAPDH, glyceraldehydes phosphodehydrogenase).
In Vivo Responses to Antigen Challenge challenge with NP-Ficoll, Act1-deficient mice developed
much higher titers of total NP-specific IgG2a and IgG2bTo examine the role of Act1 in T cell-dependent (TD)
antigen-specific responses, the Act1-deficient and lit- antibodies (Figure 3D). However, NP-specific IgM and
IgG1 production was unchanged in Act1-deficient micetermate control mice were challenged with nitro-phenol-
conjugated chicken -globulin (NP28-CGG), and specific (Figure 3D). The hyper TD and TI antigen-specific re-
sponses observed in Act1-deficient mice suggests thatantibody responses were measured (Figure 3C). Upon
in vivo challenge with NP-CGG, Act1-deficient mice de- Act1 probably plays a negative regulatory role in both
T cell-dependent and -independent humoral immuneveloped much higher titers of both total (NP30-BSA,
Figure 3C) and high-affinity (NP4-BSA, Figure 3C) NP- responses, probably through its interaction with the
CD40- and/or BAFFR-mediated pathways (Kawabe etspecific IgG2b antibodies. Although the total NP-spe-
cific IgG1 level was slightly increased (NP30-BSA, Figure al., 1994; Xu et al., 1994).
3C), the Act1-deficient mice developed significantly in-
creased high-affinity IgG1 (NP4-BSA, Figure 3C). How- Production of Autoantibodies
Dysregulation of the humoral immune response oftenever, NP-specific IgM antibody production was un-
changed in Act1-deficient mice. The Act1-deficient mice leads to autoimmune disease. Both anti-ssDNA and
anti-dsDNA IgG antibodies were detected in most of theand littermate control mice were then immunized with
the T cell-independent (TI) antigen NP-Ficoll, and spe- Act1-deficient mice, but not in the littermate control
mice (Figure 3E). Furthermore, anti-histone IgG antibod-cific antibody responses were measured. Upon in vivo
Immunity
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Figure 2. Lymphoid System Abnormality in Act1-Deficient Mice
(A) Enlarged cervical lymph node and spleen in Act1-deficient mice. Cervical lymph nodes and spleens dissected from wild-type (/) and
Act1-deficient (/) mice were compared.
(B) Histology of lymph node. Frozen sections from wild-type (/) and Act1-deficient (/) cervical lymph node were immunostained for T/B
cell zones with anti-B220 (blue) and anti-CD5 (brown); for germinal centers with biotinylated-PNA (brown) and for plasma cells with anti-
Syndecan-1 (brown).
(C) Histology of spleen. Frozen sections from wild-type (/) and Act1-deficient (/) spleens were simultaneously immunostained for
metallophilic macrophages and B cells with anti-MOMA1 (brown) and anti-B220 (blue). They were also immunostained for T/B cell zones with
anti-B220 (blue) and anti-CD5 (brown).
(D) Immunostaining of trachea. Tracheas from wild-type or Act1-deficient mice were immunostained with anti-CD3 (brown). The brown-stained
CD3 T cells are clearly detected below the epithelium in the Act1-deficient trachea.
ies were also detected in the Act1-deficient mice, but control mice that were gender matched (Table 1 and
not in the littermate control mice. Consistent with the Figure 4A). The decreased percentage of T cells in the
above conclusion that Act1 is involved in BAFF-BAFFR spleen (Thy.1, Figure 4A) was probably due to in-
pathway, transgene-mediated overexpression of BAFF creased B cells, since the total numbers of T cells per
causes breakdown of B cell tolerance and leads to pro- spleen were unaltered (Table 1). In addition to the in-
duction of autoantibodies and a SLE-like condition in creased B cell population, the dendritic cell population
mice (Gross et al., 2000; Mackay et al., 1999). (I-ACD11c) was also increased in Act1-deficient
spleen as compared to the wild-type control (Table 1).
Analysis of B220 cells in the bone marrow of Act1-Increased Peripheral B Cells
deficient mice indicated no changes in pro-B cellsWe next analyzed the T and B cell compartments of
(B220CD43IgM), pre-B cells (B220CD43IgM),thymus and spleen of Act1-deficient and littermate con-
and immature B lymphocytes (B220IgMIgD) com-trol mice by flow cytometry. The total T cells (Thy1)
partments (Table 1). Thus, lack of Act1 does not affectand the proportion of T cells in the subsets defined
the generation or differentiation of bone marrow lymphoidby CD4 and CD8 cell-surface markers were unaltered
progenitor cells that give rise to fully committed B lym-(Table 1 and data not shown). However, the total splenic
phocytes. As indicated above, B220 B cells in second-B cell (B220) population was significantly increased in
Act1-deficient spleen, as compared to that of littermate ary lymphoid organs were significantly increased (Table
Negative Regulation of B Cell Survival
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Figure 3. Antibody Production
(A and B) Serum immunoglobulin levels. (A) Sera from 7-week-old Act1-deficient mice (Act1/) (n  5), wild-type littermates (Act1/) (n 
4), CD40-deficient mice (CD40/) (n  6), double knockout mice of Act1 and CD40 (Act1/CD40/) (n  5), BAFF-deficient mice (Baff/)
(n  8), and double knockout mice of Act1 and BAFF (Act1/Baff/) (n12) were analyzed by ELISA for different immunoglobulin levels,
including IgM, IgG1, and IgG2a. (B) Sera from 8-week-old control mice (CD19creAct1/F) (n  4) and B cell-specific Act1 knockout mice
(CD19creAct1/F) (n  6) were analyzed by ELISA for IgM and IgG2a levels.
(C) T cell-dependent immune responses. Four pairs of 7-week-old Act1-deficient and wild-type littermate (/) mice were immunized with
20 g of NP28-CGG in PBS. Blood was taken at day 10 and day 14 after immunization. The sera were analyzed by ELISA for total NP-specific
antibodies with NP30-BSA or NP-specific high-affinity antibodies with NP4-BSA. Each sample was measured by using multiple dilutions, and
the data presented are an average of 50% of the maximum binding to NP4-BSA or NP30-BSA from four mice.
(D) T cell-independent immune responses. Four pairs of 7-week-old mice were immunized with 20 g/ml NP-Ficoll in PBS. Blood was taken
at day 0, day 8, and day 15 and analyzed for TI antibody isotypes with capture antigen NP30-BSA by ELISA. Data are shown here from the
blood at day 8 after immunization. Each sample was measured by using multiple dilutions, and the data presented are an average of 50% of
the maximum binding to NP30-BSA from four mice.
(E) Autoantibodies in Act1-deficient mice. Levels of circulating anti-dsDNA, anti-ssDNA, and anti-histone IgG autoantibodies in the serum of
7-month-old Act1-deficient (/) and wild-type littermate controls (/) were assayed by ELISA. The units of autoantibodies are an arbitrary
unit scale defined relative to a standard linear curve by using dilutions of monoclonal antibodies to the appropriate nuclear antigen. BWD-
1(1D12) was used to generate the anti-ds-DNA and anti-ssDNA standard curves, whereas BWH-1 (2B1) was used for the standard antihistone
curve (Kotzin et al., 1984).
1 and Figure 4A). Analysis of splenic B cells showed ment in secondary lymphoid organ. Taken together,
these results indicate that Act1 probably plays a criticalelevated mature B cells (B220IgMloIgD; Table 1), follic-
ular B cells (B220CD21intCD23hi; Figure 4B and Table regulatory role in the survival of peripheral B cells.
1), marginal zone B cells (B220CD21hiCD23lo, Figure 4B
and Table) and T1 (B220IgMhiCD21) and T2 (B220 Specific Deletion of the Act1 Gene in B Cells
To determine the role of Act1 in B cells, we decided toIgMhiCD21) transitional B cells (Figure 4C and Table 1).
These data show that the absence of Act1 led to uniform specifically delete the Act1 gene in B cells. The Act1-
deficient (Act1/) mice were first bred onto CD19creincrease in cellular components of the B cell compart-
Immunity
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Table 1. B Cell, T Cell, and Dendritic Cell Populations
Bone Marrow (	106) Act1/ Act1/ Fold
Pro-B cells (B220CD43IgM) 1.6 
 0.3 1.6 
 0.3 1.0
Pre-B cells (B220CD43IgM) 4.5 
 0.7 4.1 
 0.6 0.9
Immature B cells 3.3 
 0.6 2.9 
 0.6 0.9
(B220IgMIgD)
Recirculating mature B cells 0.43 
 0.1 0.77 
 0.1 1.8
(B220IgMloIgD)
Spleen (	106) Act1/ Act1/ Fold CD19cre/Act1/F CD19cre/Act1/F Fold
Total B cells 120.9 
 8.4 269.9 
 5.1 2.2 105.2 
 7.4 136.3 
 8.9 1.3
Mature B cells 37.5 
 1.8 102.3 
 2.0 2.7 34.9 
 3.3 52.1 
 4.8 1.5
Marginal zone B Cells 5.6 
 0.4 18.4 
 0.8 3.3 6.2 
 0.6 12.8 
 1.3 2.1
Follicular B cells 31.1 
 1.7 77.6 
 2.1 2.5 28.9 
 2.4 40.9 
 4.1 1.4
T1 transitional B cells 8.2 
 0.3 16.0 
 1.0 1.9 6.8 
 0.7 9.6 
 0.9 1.4
T2 transitional B cells 4.1 
 0.3 10.2 
 0.5 2.5 3.6 
 0.4 5.5 
 0.5 1.5
Dendritic cells 6.1 
 1.0 15.8 
 2.2 2.6 4.2 
 0.4 5.8 
 0.7 1.4
Total T cells 37.7 
 3.0 34.2 
 2.1 0.9 43.5 
 4.1 43.9 
 3.7 1.0
CD4 cells 27.1 
 2.3 24.4 
 3.1 0.9 31.1 
 2.8 31.6 
 3.1 1.0
CD8 cells 10.6 
 1.0 9.5 
 0.5 0.9 12.4 
 1.1 12.1 
 1.2 1.0
Total B cells (B220), mature B cells (B220IgM1oIgD), marginal zone B cells (B220CD21hiCD23lo), follicular B cells (B220CD21intCD23hi), T1
transitional B cells (B220IgMhiCd21-), T2 transitional B cells (B220IgMhiCD21), dendritic cells (I-ACD11c); total T cells (Thy.1).
Data are shown as mean 
 SEM. from three pairs of mice each group. Fold stands for the ratio of cell number from Act1 knockout mice to
cell numbers from Act1 control mice. BM cell counts represent the number of cells isolated from two hindleg femurs. Mice were age (6–8
weeks) and gender matched.
transgenic mice (CD19cre/ [Li et al., 2003]) to generate These cultured cells were examined for cell survival by
flow cytometry by using forward light scatter (FSC)/sideCD19cre/Act1/ mice. These mice were further bred
onto Act1 floxed mice (Act1flox/flox) to generate the control light scatter (SSC) plots (Rolink et al., 2002) (Supplemen-
tal Figure S4A). Treatment of wild-type splenocytes withmice (CD19cre/Act1/flox) and B cell-specific knockout
mice (CD19cre/Act1/flox). The deletion efficiency me- CD40 antibody for 4 days increased the percentage of
live cells from 7.0 to 22.2, whereas the same stimulationdiated by CD19 promoter driven Cre was about 80% as
determined by Southern blot with the prb3 (Figure 1 increased the viability of Act1-deficient splenocytes,
from 5.2% to 38.7% (Figure 5A). BAFF treatment also ledand Supplemental Figure S1). We found that the B cell-
specific Act1 knockout mice (CD19cre/Act1/flox) had to greater increase in cell survival in the Act1-deficient
splenocytes, as compared to the cells from littermatesimilar phenotypes as the Act1-deficient mice, although
with less severity. The CD19cre/Act1/flox mice devel- control mice (Figure 5A). However, IL-4- and IgM-medi-
ated B cell survival was unaltered in Act1-deficient miceoped enlarged lymph nodes and spleen (data not
shown). Hypergammaglobulinemia was also detected in (Figure 5A and data not shown). It is important to point
out here that CD40- and BAFF-mediated cell survivalthese mice (Figure 3B). While the T cell population was
not altered, the total B cell population and all the subsets was also enhanced in splenic B cells isolated from B
cell-specific Act1 knockout mice (Figure 5B), indicatingof B cells were increased in the CD19cre/Act1/flox
(Table 1). These results strongly indicate that Act1 plays an intrinsic defect in Act1-deficient B cells. We then
examined the role of Act1 in CD40-mediated B cell prolif-an important role in B cells, which is consistent with the
phenotype observed in the Act1-deficient mice. Interest- eration. CD40-mediated proliferation was increased by
40% in Act1-deficient B cells as compared to that iningly, the dendritic cell population was also increased
in these B cell-specific Act1 knockout mice, suggesting wild-type cells (Supplemental Figure S4B), which proba-
bly contributes to the enhanced CD40-mediated B cellthat the defect in B cells may have an indirect impact
on the dendritic cells. survival in Act1-deficient mice described above (Fig-
ure 5A).
The prosurvival proteins Bcl-xl and Bcl2 have beenIncreased CD40- and BAFFR-Mediated
implicated in CD40- and BAFFR-mediated B cell survivalB Cell Survival
(Mackay et al., 2003). Western blot analysis showed thatWhile CD40- and CD40L-deficient mice showed loss
Act1-deficient B cells had much induced levels of Bcl-of T cell-dependent B cell survival, proliferation, and
xl in response to stimulation with CD40 antibody (Figureactivation, recent studies have also demonstrated the
5C), strongly suggesting that Bcl-xl is probably one ofimportance of BAFF-BAFFR interaction in B cell survival
the important effectors responsible for Act1-regulated(Mackay et al., 2003; Mackay and Browning, 2002). The
CD40-mediated B cell survival.fact that Act1-deficient mice and B cell-specific Act1
knockout mice showed increased peripheral B cells im-
plicates a possible role of Act1 in CD40- and BAFFR- Increased CD40- and BAFFR-Mediated Signaling
We determined whether Act1 had any direct effects onmediated B cell survival. To test this hypothesis, resting
mature B cells were purified from spleen and cultured the immediate signaling events mediated by CD40 and
BAFF. Act1-deficient B cells showed stronger IB phos-with or without anti-CD40 antibody or BAFF for 4 days.
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Figure 4. FACS Analysis
Splenocytes from 7-week-old Act1-deficient (/) (n  3) and wild-type littermate control (/) (n  3) mice were stained with the indicated
antibodies, and then analyzed after electronic scatter gating.
(A) Increased B220 cells in Act1-deficient spleen.
(B) Increased follicular (CD21intCD23hi) and marginal zone (CD21hiCD23lo) B cells in Act1-deficient spleen.
(C) Increased transitional B cells in Act1-deficient spleen. The data are presented as percentages of total splenocytes from one pair of mice.
Similar results were obtained from three pairs of mice. Since the Act1-deficient spleens were enlarged, the different B cells populations are
presented as actual cell numbers in Table 1.
phorylation and enhanced p100 processing to p52 in As controls, we showed that the levels of April- (a ligand
for TACI, BCMA, but not BAFFR) and BCR-mediatedresponse to CD40 antibody and BAFF stimulation, impli-
cating a negative regulatory role of Act1 in both canoni- signaling are the same between wild-type and Act1-
deficient B cells (Figures 6D and 6E).cal and noncanonical NFB activation pathway (Figures
6A–6C). Interestingly, the CD40-induced IB phosphory- In addition to B cells, we also examined the role of
Act1 in CD40- and BAFFR-mediated signaling in primarylation was much stronger than that induced by BAFF
treatment in Act1-deficient B cells. As activation of NFB mouse embryonic fibroblasts (MEFs) (Supplemental Fig-
ure S6). Act1-deficient MEFs showed increased CD40-(through the canonical pathway) induces the expression
of p100, Act1-deficient B cells showed higher levels of and BAFFR-mediated NFB-dependent E-selectin pro-
moter activity, indicating that Act1 can also negativelyNFB2/p100 precursor in response to CD40 antibody
stimulation (Figure 6A). Furthermore, Act1-deficient B regulate the CD40- and BAFFR-mediated signaling in
non-B cells.cells showed enhanced activation of MAP kinases, in-
cluding JNK, ERK, and p38 in response to CD40 anti-
body and BAFF (Figures 6B and 6C and data not shown). Interaction of Act1 with Other Signaling Molecules
To elucidate the mechanism of action of Act1, we as-It is important to point out here that the expression of
CD40-CD40L and BAFF-BAFFR was not altered in Act1- sessed its interaction with known components of the
CD40 and BAFFR pathway. Endogenous Act1 was re-deficient mice as compared to wild-type controls (Figure
6B, Supplemental Figure S5 and data not shown). Taken cruited to CD40 and BAFFR upon CD40L and BAFF
stimulation in the B cell line IM9 and as well as in primarytogether, these results indicate that Act1 negatively reg-
ulates the CD40- and BAFFR-mediated pathways, which human splenocytes (Figures 7A–7C). Since TRAF mole-
cules have been shown to function as important adapt-probably results in its inhibitory effect on B cell survival.
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Figure 5. B Cell Survival
(A) Enhanced B cell survival in Act1-deficient mice. Purified splenic B cells from 7-week-old Act1-deficient (/) and littermate control (/)
mice untreated or treated with CD40 antibody for 4 days. These cultured B cells were then analyzed by flow cytometry on FSC/SSC plots
(Supplemental Figure 4A). Annexin V staining for apoptotic cells and PI staining for dead cells were used in the FACS analysis. The data
presented are the average of percentage of cell survival from three pairs of mice.
(B) Increased percentage of live B cells from B cell-specific Act1 knockout mice upon stimulation with CD40 antibody or BAFF ligand. The
data are shown as the average of percentage of B cell survival from B cell specific Act1 knockout mice (CD19creAct1/F) and control mice
(CD19creAct/F).
(C) Enhanced CD40-mediated induction of Bcl-xl in Act1-deficient splenic B cells. Splenic B cells from 7-week-old Act1-deficient (/) and
littermate control (/) were untreated or treated with CD40 antibody or BAFF for 24 hr or 48 hr. The cell extracts were analyzed by Western
blot with the antibodies against Bcl-xl and Bcl-2. -Tubulin was used as a loading control. The Bcl-xl levels were analyzed by Scion Image
1.62C alias and presented as relative fold of induction of the untreated samples.
ers for CD40 and BAFFR, we examined the interaction nomegaly, hypergammaglobulinemia, inflammation in
multiple tissues, and the formation of autoantibodies.between Act1 and different TRAFs. Previously, Act1 was
shown to specifically interact with TRAF3, but not with While the B cell-specific Act1 knockout mice displayed a
similar phenotype, the SLE-like pathologies of the Act1-the other TRAFs when they were overexpressed in 293T
cells (Qian et al., 2002). Under conditions of normal ex- deficient mice were blocked in CD40-Act1 and BAFF-
Act1 double knockout mice.pression, endogenous Act1 interacted strongly with
TRAF3, weakly with TRAF2, but failed to interact with The enhanced CD40- and BAFF-induced p100 pro-
cessing of p52 in the Act1-deficient B cells is likely toTRAF6 upon CD40L stimulation as revealed by coimmu-
noprecipitation (Figure 7A). On the other hand, endoge- be important for the expanded B cell compartment in
the Act1-deficient spleen. Nevertheless, the enhancednous Act1 interacted with TRAF3, but not with TRAF2
or TRAF6 upon stimulation with BAFF (Figure 7B). Taken canonical NFB activation pathway and the activation of
MAP kinases probably also contribute to the increasedtogether, these preliminary results suggest that Act1
might regulate the CD40- and BAFFR-mediated signal- survival of Act1-deficient peripheral B cells. The control
of cell survival is believed to rely on the regulation ofing through its interaction with the TRAF molecules,
particularly TRAF3. key antiapoptotic and proapoptotic regulators. Previous
studies have shown that antiapoptotic proteins Bcl2 and
Bcl-xl play important roles in B cell survival. Interest-Discussion
ingly, we found that stimulation with anti-CD40 resulted
in a much higher levels of Bcl-xl in the Act1-deficient BThis manuscript shows that CD40- and BAFF-mediated
survival is significantly increased in Act1-deficient B cells than in the wild-type control cells. These elevated
levels of Bcl-xl provide a mechanism for the increasedcells, implicating a negative or attenuating regulatory
role of Act1 in B cell survival. Consistent with this finding, CD40-mediated B cell survival in the Act1-deficient
mice. BAFF stimulation did not increase the levels ofAct1-deficient mice revealed a general increase in pe-
ripheral B cells, culminating in lymphadenopathy, sple- Bcl-xl, indicating that B cell survival is probably not
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Figure 6. Increased CD40 and BAFF Signaling in Act1-Deficient Splenic B Cells
Splenic B cells from 7-week-old Act1-deficient (/) and littermate control (/) mice were untreated or treated with CD40 antibody, mBAFF,
anti-IgM or mApril for the indicated times. The whole cell extracts were examined by western blot analysis.
(A) Cells were treated with CD40 antibody or BAFF for 3, 6, or 24 hr, and extracts were analyzed with antibodies against P100/P52 and -tubulin.
(B) Extracts from cells treated with CD40 antibody were analyzed with antibodies against p-IB, IB, p-ERK, ERK, and CD40.
(C) Extracts from cells treated with BAFF were analyzed with antibodies against p-IB, IB, p-ERK, ERK, and tubulin.
(D) Extracts from cells treated with anti-IgM were analyzed with antibodies against p-ERK and ERK.
(E) Extracts from B cells treated with mApril for different times were analyzed with antibodies against p-I-B and Actin. -tubulin and Actin
were used as a loading control. The levels for p52, p-IB, p-ERK, and p-JNK were analyzed by Scion Image 1.62C alias and presented as
relative fold of induction of the untreated samples.
dependent on this antiapoptotic factor in Act1-deficient TRAF2 to CD40 was increased upon CD40 engagement,
suggesting that TRAF3 may exert its inhibitory effectsmice. While Act1-deficient B cells showed similar levels
of p100 processing in response to CD40 antibody and on CD40 signaling by competing with TRAF2 for associ-
ation with CD40. Moreover, TRAF3 was shown to inter-BAFF, the CD40-induced IB phosphorylation was much
stronger than that induced by BAFF treatment. The dif- act with NIK, targeting NIK for degradation by the pro-
teasome and inhibiting NIK-mediated p100 processing.ferential effects of Act1 on CD40- and BAFF-mediated
pathways probably result in altered expression of differ- It is possible that Act1 exerts its inhibitory role in CD40
and BAFFR signaling through its interaction with TRAF3ent target genes in Act1-deficient cells. Future efforts
are directed toward identifying the Act1-modulated tar- by either competing with the positive regulators (such
as TRAF2) for interactions with receptors and kinases orget genes that are responsible for attenuating CD40-
and/or BAFF-mediated B cell survival. targeting the positive regulators for degradation through
the proteasome pathway. Interestingly, the expressionThe fact that Act1 specifically interacts with TRAF3
upon stimulation with CD40L and BAFF suggests that of both Act1 and TRAF3 are increased in mouse splenic
B cells upon stimulation with BAFF, CD40L, and LPSTRAF3 may play an important role in Act1-mediated
negative regulation. Interestingly, TRAF3 has been (Grammer and Lipsky, 2000) (unpublished data, Z. Zhao
and X.L.), suggesting that these two molecules mightshown to play a negative regulatory role in both CD40
and BAFFR signaling (Xu and Shu, 2002; Hostager et work together as a feedback control to dampen signal-
ing for B cell survival and activation, regulating homeo-al., 2003; Xie et al., 2004; Liao et al., 2004). TRAF3/ B
cells displayed enhanced CD40-mediated JNK activa- stasis of B cell functions.
While we have now clearly shown that Act1 plays ation. Furthermore, in TRAF3/B cells, the recruitment of
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Figure 7. CD40L- and BAFF-Induced Interaction of Act1 with CD40, BAFFR, and TRAF3
Cell extracts from IM9 (A and B) or primary human splenocytes (C) untreated or treated with CD40L (A) or BAFF (B and C) for the indicated
times were immunoprecipitated with anti-Act1, followed by Western analyses with antibodies against CD40 (A), BAFFR (B and C) Act1 (A–C),
TRAF3 (A and B), TRAF2 (A and B) and TRAF6 (A and B).
negative role in CD40 and BAFF-mediated pathways, affected in Act1-deficient mice (Supplemental Figure
S4C), we still cannot completely exclude possible func-our previous studies showed that overexpression of
Act1 can lead to constitutive NFB activation. One pos- tions of Act1 in T cells. Therefore, in addition to our
effort to understand the detailed mechanism of CD40-sibility is that Act1 may play differential functions in
different cell types. However, we found that CD40- and Act1- and BAFFR-Act1-mediated signaling in B cells,
future research will also explore the role of Act1 in otherBAFF-mediated signaling is also elevated in Act1-defi-
cient MEFs, suggesting that Act1 is able to function as TNFR-mediated signaling pathways in different cell
types by breeding conditional Act1-deficient mice ontoa negative regulator in cell types other than B cells.
Furthermore, siRNA knocking down of Act1 in Hela cells cell- and tissue-specific Cre-transgenic mice.
led to enhanced CD40-mediated JNK activation, indicat-
Experimental Proceduresing that Act1 also functions as a negative regulator in
cultured epithelial cells (Supplemental Figure S7). Our
Generation of Act1-Deficient Mice
recent results suggest that the Act1-mediated constitu- The Act1 genomic clone was obtained from screening of a 129/sv
tive NFB activation is probably due to nonspecific pro- BAC library. The HindIII/BamHI genomic fragment containing exon
2 of the Act1 gene (residuals 1–268, containing the first ATG) wastein-protein interaction carried out by overexpression
subcloned into the Tri-Neo vector (containing three loxP sites). Whileof Act1. Interestingly, when Act1 and TRAF3 were co-
the neomycin-resistance gene (Neo) was inserted between the firsttransfected into 293T or Hela cells, TRAF3 specifically
and the second loxP sites, HindIII/BamHI genomic fragment con-and completely inhibited Act1 mediated NFB activa-
taining exon 2 of the Act1 gene was flanked by the second and the
tion, whereas TRAF3 had no effect on IRAK-mediated third loxP sites. The resulting DNA fragment including lox-Neo-lox-
NFB activation (Supplemental Figure S7). This result exon2-lox was then subcloned into the pBS (pBlueScript) vector.
For construction of the Act1 gene-targeting vector, the 5 arm (orindicates that when Act1 is in complex with its natural
left arm [LA] consisting of a 3.2 kb fragment from the first intron ofinteraction partner (TRAF3), Act1 does not lead to NFB
the Act1 gene) was subcloned upstream of lox-Neo-lox-exon2-loxactivation. Upon Act1 overexpression, Act1 probably
in pBS, while the 3 arm (or right arm [RA] consisting of a 4.0 kbinteracts nonspecifically with other signaling molecules,
fragment from the second intron of the Act1 gene) was subcloned
resulting in constitutive NFB activation. downstream of lox-Neo-lox-exon2-lox in pBS. Diphtoxin A gene
In addition to its role in CD40 and BAFFR signaling in was inserted downstream of the 3 arm for negative selection. The
resulting Act1 gene-targeting vector was then linearized with NotI,B cells, Act1 may also play a role in other cell types in
electroporated into 129/sv ES cells, and then followed by selectionsignaling events mediated by other members of the
for G418-resistant ES clones. The G418-resistant ES clones wereTNFR superfamily, especially the subset of TRAF3-utiliz-
then transfected with Cre to remove the Neo drug marker and exoning TNFRs. The fact that the dendritic cell population is
2 of Act1, followed by Southern blots with two probes (prb1 and
increased in Act1-deficient mice suggests a potential prb2) located outside of each end of the targeting construct. Tar-
role of Act1 in dendritic cell maturation and survival. geted ES cells (Act1 null) were injected into mouse blastocysts to
generate wild-type, heterozygous, and homozygous mice (BALB/c).Although the T cell population and proliferation is not
Negative Regulation of B Cell Survival
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Act1-deficient mice and their age- and gender-matched wild-type For T cell-dependent antigen-specific IgM, IgG1, and IgG2b, anti-
body titers were determined as described for isotype-specific ELI-littermates from these intercrosses were used for experiments. The
Cleveland Clinic Foundation Animal Research Committee approved SAs, except that plates were coated with 5 g/ml capture antigen of
either NP4-BSA or NP30-BSA. Data for the antigen specific antibodiesall of the animal protocols used in this study.
were presented as reading at 405 nm with serum dilution of 1:100.
For T cell-independent antigen-specific IgM, IgG1, IgG2a, andGeneration of B Cell-Specific Act1-Deficient Mice
IgG2b, plates were coated with 5  g/ml capture antigen of NP30-To generate B cell-specific Act1 knockout mice, the Act1-deficient
BSA. Autoantibodies to histone, dsDNA, and single-stranded DNAmice were bred onto CD19cre mice (CD19cre/) to generate
(ssDNA) were measured by ELISA as previously described (Vyse etCD19cre/Act1/ mice. These mice were further bred onto Act1
al., 1996).floxed mice (Act1flox/flox) to generate control mice (CD19cre/
Act1/flox) and B cell-specific knockout mice (CD19cre/Act1/flox).
CD19cre-mediated deletion efficiency was determined by Southern Immunizations
blot with the probe (prb3) shown in Figure 1. 7-week-old wild-type or Act1-deficient mice were immunized intra-
peritoneally with 20 g of NP28-CGG for TD response or 20 mg of
NP-Ficoll for TI response (Biosource Technologies, Vacaville, CA).Generation of the CD40-Act1 and BAFF-Act1
On days 10 and 14 after immunization for TD or days 8 and 15 forDouble Knockout Mice
TI, serum was collected from peripheral blood. Circulating antibod-To generate the double knockout mice, Act1 complete knockout
ies were measured by an isotype-specific, antigen-specific ELISA.mice (Act1/) were first bred onto CD40 knockout mice (CD40/)
NP30-BSA was used to capture all antigen-specific Igs, whereas NP4-(purchased from Jackson Laboratory; Kawabe et al., 1994) or BAFF
BSA was used to capture only high-affinity Igs. Captured antibodiesknockout mice (BAFF/) to first generate heterozygous mice
were detected with enzyme-conjugated rabbit anti-IgM, anti-IgG1,(Act1/CD40/ or Act1/BAFF/), then CD40 null Act1 heterozy-
anti-IgG2a, and anti-IgG2b.gous mice (CD40/Act1/), and BAFF null Act1 heterozygous mice
(BAFF/Act1/). These mice were then bred among themselves
to generate CD40-Act1 and BAFF-Act1 double knockout mice. Immunohistochemistry
Spleens were embedded in OCT compound (Tissue-Tek, Sakura,
Southern and RNA Blots Torrance, CA) and slowly frozen over liquid nitrogen and stored
Genomic DNA was extracted from ES cells or mouse tail tissue, at 90C. Cryostat sections were incubated with biotinylated anti-
digested with HindIII or KpnI / SpeI (New England Labs), separated B220, anti-CD5, anti-Syndecan-1 (BD Pharmingen, San Diego, CA),
by 1% agarose gel electrophoresis, and analyzed with either a 5 biotinylated-PNA (Vector Labs, Burlingame, CA), or biotinylated anti-
external (prb1 for DNA digested with KpnI /SpeI) or a 3 external MOMA1(Bachem, King of Prussia, PA). Sections were developed
probe (prb2 for DNA digested with HindIII). For RNA analysis, total by using the avidin/biotin system (Vecastain ABC kit, Vector Labs,
RNA was isolated by using Trizol reagent (Invitrogen) according to Burlingame, CA) per the manufacturer’s instructions. Slides were
the manufacturer’s instruction. mounted in Crystal Mount (Biomeda, Foster City, CA) and analyzed
with a Nikon E800 microscope.
Western Blot Analysis
Splenic B cells were untreated or treated 2 g/ml anti-mouse CD40 Coimmunoprecipiations
antibody (BD pharmingen), 2 g/ml anti-IgM (Jackson Immuno- Primary human splenocytes were isolated from discarded human
Research), 10 ng/ml TNF (Peprotech), 0.1 g/ml mouse BAFF li- spleen tissue of cadaver transplant donors and cultured in 10%
gand (Apotech Biochemicals, Epalinges, Switzerland), or 0.2 g/ml FCS  RPMI. Human B cell line IM9 was cultured in 10% FCS 
mouse April ligand (generously provided by Amgen, Inc., California) RPMI. Immunoprecipitations were performed on these cells as pre-
for different time points. Western analyses were performed with viously described (Qian et al., 2002). Antibodies used for immuno-
antibodies against phospho-JNK, JNK, phospho-IBa, IBa, phos- precipitations include CD40 (H120, Santa Cruz Biotechnology),
pho-ERK, ERK, phospho-P38, P38 (Cell Signaling, Beverly, MA) and BaffR (Prosci, Inc.), TRAF2 (C20, Santa Cruz Biotechnology), TRAF3
CD40, Bcl2, Bcl-xL, -tubulin, Actin (Santa Cruz Biotechnology, CA), (H122, Santa Cruz Biotechnology), TRAF6 (H274, Santa Cruz Bio-
and P100/P52 (kindly provided by Dr. Green, La Jolla Institute for technology), and Act1 (Qian et al., 2002).
Allergy and Immunology, San Diego, CA).
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